Melijent-M 1000/2.5 is an oral combination tablet containing **Linagliptin (a DPP-4 inhibitor)** and **Metformin (a biguanide)**, produced by Alhavi Pharmaceutical.
It is prescribed for the management of blood glucose levels in adults with type 2 diabetes mellitus.
The complementary mechanisms of these two active ingredients provide enhanced glycemic control — Linagliptin increases insulin secretion and decreases hepatic glucose production, while Metformin reduces glucose synthesis and improves insulin sensitivity.
This formulation allows dual-action therapy in a single tablet for better compliance and efficacy.
Melijent-M 1000/2.5 (Linagliptin + Metformin)
Dosage form: Tablet
Melijent-M 1000/2.5 is indicated for:
• Control of blood glucose levels in adults with type 2 diabetes mellitus who require combination therapy with Linagliptin and Metformin
• Can be used as an adjunct to diet and exercise, alone or with other antidiabetic medications
The combination works synergistically to improve insulin response and reduce hepatic glucose output for optimal glycemic control.
• Recommended dose: **2.5/1000 mg twice daily**
• Take **with or immediately after meals** to reduce gastrointestinal side effects associated with Metformin
• Swallow the tablets whole with water — do not crush or chew
• Continue following dietary and exercise recommendations advised by your physician
• Use under medical supervision with regular monitoring of blood glucose and kidney function